**Supplementary Data**

FISH analysis or ctDNA analysis for *MET* amplification was performed on enrolled patients (N=45).

|  |
| --- |
| **Supplementary Table S3.** Enrolled patients (N=45) |
| **Patient**  | **FISH****tumor cells with *MET/CEP7* ≥2****(mean *MET/CEP*), %** | **ctDNA****copy number****baseline/end of therapyb** | ***MET* amplified****Yes/No** | **Objective response****Yes/No** |
| Dose escalation |
| 1Aa1B | 63 (1.92)54 (2.43) | 1.42 | Y | N |
| 2 | 0 (1.04) | 1.16 | N | N |
| 3 | 0 (0.77) | 0.99 | N | N |
| 4 | 6 (1.12) |  | N | N |
| 5 | 3 (1.12) | 1.02 | N | N |
| 6 | 5 (1.12) |  | N | N |
| 7 | 7 (1.38) | 1 | N | N |
| 8 | 1 (0.98) |  | N | N |
| 9 | 33 (1.76) | 1.14/0.96 | Y | Y |
| 10 |  |  |  | N |
| 11 | 0 (1.06) |  | N | N |
| 12 |  |  |  | N |
| 13 | 0 (0.97) |  | N | N |
| 14 |  |  |  | N |
| 15 |  |  |  | N |
| Expansion cohort |
| 16 |  | 0.86 | N | N |
| 17 |  | 0.64 | N | N |
| 18 | 4 (1.11) | 1.04 | N | N |
| 19 | 6 (1.05) |  | N | N |
| 20A20B | 0 (0.54)100 (6.91) | 6.34/3.34 | NY | Y |
| 21 | 18 (1.19) |  | N | N |
| 22 |  |  |  | N |
| 23Aa23B | FISH *MET*– (Caris; Irving, TX)99 (7.81) | 1.86/1.78 | Y | Y |
| 24 | 27 (1.29) | 1.03 | Y | N |
| 25 | 0 (1.01) | 1.08 | N | N |
| 26  | 10 (1.16) | 0.79 | N | N |
| 27  | 0 (0.93) |  | N | N |
| 28Ac28B | 0 (0.97)NGS *MET* amp (Foundation Medicine) | 6.47/10.54 | Y | N |
| 29  | 12 (1.07) | 1.08 | N | N |
| 30  |  | 1.08 | N | N |
| 31  | 2 (0.96) |  | N | N |
| 32  |  |  |  | N |
| 33  |  |  |  | N |
| 34  |  | 1.1 | N | N |
| 35  | 4 (1.04) | 0.99 | N | N |
| 36  |  | 0.91 | N | N |
| 37  | 0 (0.84) |  | N | N |
| 38  | 26 (1.74) | 1.06 | Y | N |
| 39  |  | 0.89 | N | N |
| 40  |  |  |  | N |
| 41  |  | 1.07 | N | N |
| 42  | 41 (2.5) | 1.02 | Y | Y |
| 43 | 92 (6.4) | 1.97 | Y | N |
| 44  |  |  |  | N |
| 45  | 42 (1.76) |  | Y | N |
| aFISH analysis of primary tumor (A); FISH analysis of recurrent tumor (B); graphed in Figure 2B.bctDNA baseline/end of treatment when performed.cPatient with *MET* amplification detected by Foundation Medicine (Cambridge, MA) sequencing of recurrent metastatic lesion; no tissue available for FISH testing of recurrent NGS+ tumor.ctDNA, circulating tumor DNA; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing. |